

Ref.: NLL/CS/2025-467

March 10, 2025

**To**

1. National Stock Exchange of India Limited  
Listing Department,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai 400 051

**Symbol: NECLIFE**

2. BSE Limited  
Corporate Relationship Department,  
P J Towers, Dalal Street,  
Mumbai 400 001

**Scrip Code: 532649**

**Sub: Update on EU regulatory inspection.**

**Ref: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations 2015.**

Dear Sir/ Madam,

This is to inform that API manufacturing facility, located at U-2, Village Saidpura, Tehsil Dera Bassi, District SAS Nagar (Mohali), Punjab of the Company, has recently undergone a joint inspection conducted by the European Directorate for the Quality of Medicines & HealthCare (EDQM) and the Spanish Agency of Medicines and Medical Devices (AEMPS). This inspection aimed to assess of compliance with EuGMP standards. Following the inspection, seven observations including four critical, were noted.

The Company is in the process of preparing a Corrective Action and Preventive Action (CAPA) report to address the observations. The Company upholds quality and compliance with utmost importance and remain committed to be compliant with the cGMP quality standards.

The European regulator will conduct a re-inspection of the facility to verify the compliance and CAPA submitted which may lead to EuGMP approval.

Kindly take the same on record and oblige.

Thanking you,

Yours faithfully,  
For **Nectar Lifesciences Limited**

(Amit Chadah)  
**Chief Executive Officer**